tailieunhanh - Báo cáo y học: "α Tumor necrosis factor-α blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: α Tumor necrosis factor-α blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification? | Available online http contents 7 3 121 Commentary Tumor necrosis factor-a blockade in ankylosing spondylitis a potent but expensive anti-inflammatory treatment or true disease modification Filip Van den Bosch Filip De Keyser Herman Mielants and Eric M Veys University Hospital Department of Rheumatology Gent Belgium Corresponding author Filip Van den Bosch Published 11 April 2005 This article is online at http content 7 3 121 2005 BioMed Central Ltd Arthritis Research Therapy 2005 7 121-123 DOI ar1742 See related research by Baraliakos et al. http content 7 3 R439 Abstract Blocking tumor necrosis factor-a either with monoclonal antibodies or with soluble receptor constructs has been proven to be effective with an acceptable safety profile in patients with rheumatoid arthritis and more recently also in the diseases belonging to the spondyloarthropathy concept. Nevertheless multiple questions still remain unresolved especially concerning longer-term treatment. Data from a recent manuscript by Baraliakos and colleagues seem to indicate that at least for the vast majority of ankylosing spondylitis patients treatment with infliximab can not be withdrawn if one wants to control disease activity in a continuous way. Although still unproven this might be of crucial importance with regard to structure modification and prevention of ankylosis in this chronic inflammatory disorder. A few years ago rheumatologists treating patients with ankylosing spondylitis AS had to accept the fact that the only goal of their proposed treatment was to alleviate pain and stiffness. Disease modification let alone cure of the disease was an unrealistic endpoint. The advent of so-called biological therapies at the end of the second millennium provoked a therapeutic breakthrough seldom witnessed in the field of rheumatology. Inhibition of tumor necrosis factor-a TNF-a proved highly efficacious